Weight gain during the dolutegravir transition in the African Cohort Study

INTRODUCTION: Dolutegravir (DTG) has become a preferred component of first‐line antiretroviral therapy (ART) in many settings but may be associated with excess weight gain. We evaluated changes in weight and body mass index (BMI) after switch to single‐tablet tenofovir/lamivudine/dolutegravir (TLD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Esber, Allahna L., Chang, David, Iroezindu, Michael, Bahemana, Emmanuel, Kibuuka, Hannah, Owuoth, John, Singoei, Valentine, Maswai, Jonah, Dear, Nicole F., Crowell, Trevor A., Polyak, Christina S., Ake, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008168/
https://www.ncbi.nlm.nih.gov/pubmed/35419973
http://dx.doi.org/10.1002/jia2.25899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008168/
https://www.ncbi.nlm.nih.gov/pubmed/35419973
http://dx.doi.org/10.1002/jia2.25899

Ejemplares similares